Eli Lilly (NYSE:LLY) saw its shares climb 6.5% to $1,200.98 in Friday trading, adding approximately $65.7 billion to its market capitalization. The surge was fueled by a combination of regulatory catalysts: a positive recommendation from the European Medicines Agency's CHMP for its leukemia drug Jaypirca, and the announcement of Medicare GLP-1 Bridge coverage for obesity drugs effective July 1.
The stock's weight in the Health Care Select Sector SPDR Fund (NYSEARCA:XLV) played a critical role in amplifying its impact. With Lilly accounting for 15.84% of the ETF as of June 25, its rally contributed roughly 1.03 percentage points to XLV's 2.4% gain, representing about 43% of the fund's move. This underscores how a single heavyweight can sway the broader healthcare sector, especially when the broader market showed little movement.
While the Jaypirca recommendation was a positive development, its financial significance pales compared to the GLP-1 opportunity. Jaypirca generated only $165 million in first-quarter sales, a fraction of Lilly's total $19.8 billion in revenue. In contrast, the company's GLP-1 drugs Mounjaro and Zepbound collectively brought in $12.8 billion in the same period. Investors are clearly focused on the massive addressable market for obesity treatments.
The Medicare GLP-1 Bridge program, which begins July 1 and runs through December 31, 2027, will provide coverage for certain Part D beneficiaries. Lilly's executive Ilya Yuffa noted that approximately 20 million Medicare patients may meet clinical criteria, making obesity treatment more accessible. The program operates outside standard Part D payment structures, offering a window for demand growth before full payer economics are determined for 2027-2028.
Global Expansion and Pricing Challenges
Beyond the U.S., Lilly is preparing for international expansion. Executive VP Patrik Jonsson indicated that orforglipron, an oral GLP-1 candidate, could reach China between late 2026 and early 2027. GLP-1 sales through Chinese e-commerce platforms totaled about 1.4 billion yuan ($207 million) in the first quarter, according to Jefferies. However, Europe presents pricing headwinds, as Jonsson acknowledged that most-favored-nation pricing will play a role in all launches.
Wall Street remains broadly bullish on Lilly, with 20 of 22 analysts rating it a Buy and an average 12-month price target of $1,290.79. Leerink's David Risinger maintained a Buy rating and a $1,232 target, slightly above the closing price. The company is scheduled to report second-quarter earnings on August 5, which will provide further clarity on its growth trajectory.
